Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...

If authorised, Vimkunya would be the first vaccine in the EU to protect adolescents aged 12 to 17 against Chikungunya.

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya ...

Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...

Chikungunya infections began to increase by the end of September 2022 in Paraguay, which declared on Feb. 24 that it was on alert due to the “atypical clinical and epidemiological behavior” of ...

Cases of Chikungunya among children are being reported in recent days, Lady Ridgeway Hospital’s Consultant Paediatrician Dr. Deepal Perera said.Dr. Perera highlighted that the disease is spread by ...

Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different ...

Chikungunya infected children are being reported these days, said Dr. Deepal Perera, a specialist at the Lady Ridgeway ...

Chikungunya is a disease that is caused by the chikungunya virus which is transmitted to humans by infected mosquitoes. Its name is derived from a word in the Makonde language that means contorted or ...

Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially life ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

Maharashtra witnessed a significant rise in chikungunya cases this year, with 5,757 infections. Patients are experiencing prolonged after-effects like joint pain, fatigue, and neurological ...